Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.50    -0.002 (-0.40%)
Bid:
0.44
Ask:
0.568
Spread: 0.128 (29.091%)
Market Cap: £2.91m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Block Listing Update

22 May 2017 07:00

RNS Number : 7387F
Futura Medical PLC
22 May 2017
 

For immediate release

22 May 2017

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Block Listing Update

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology today announces that an application has been made to the London Stock Exchange to extend its block listings of securities in respect of a total of 3,360,000 ordinary shares of 0.2 pence each (the "Ordinary Shares") which may arise pursuant to the exercise of options under its Unapproved Share Option Scheme ("USOS") and its EMI Share Option Scheme ("EMI").

Admission of the above additional shares to be block listed is expected to occur on or around 25 May 2017.

The Company makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares.

The table below provides further detail:

 

Name of company:

Futura Medical plc

Name of scheme(s):

USOSEMI

Period of return:

From:

25 November 2016

To:

22 May 2017

 

Number and class of securities not issued under the scheme(s) at beginning of period

 

USOS:

 

1,156,321

EMI:

1,364,141

Total:

2,520,462

 

Number and class of securities admitted to the scheme(s) in the period

USOS:

1,466,208

EMI:

1,893,792

Total:

3,360,000

 

Number of securities issued under the scheme(s) during the period

 

Number of securities lapsed under the scheme(s) during the period

USOS:

(176,419)

EMI:

 

USOS:

EMI:

 

(236,543)

 

-

-

 

Balance of securities under the scheme(s) not yet issued at the end of the period

USOS:

2,446,110

EMI:

3,021,390

Total:

5,467,500

Number and class of securities originally admitted and the date of admission

USOS:

814,424 on 25 May 2011, 1,202,280 on 8 October 2013,

1,466,208 on 25 May 2017

 

USOS Total:

3,482,912

 

 

EMI:

1,520,576 on 25 May 2011, 1,467,720 on 8 October 2013,

1,893,792 on 25 May 2017

 

EMI Total:

4,882,088

 

 

Total:

8,365,000

 

 

Name of contact:

Derek Martin, Chief Financial Officer

 

Telephone number of contact:

+44 (0) 1483 685 670

 

 

 

For further information please contact:

 

Futura Medical plc

 

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

 

N+1 Singer (Nominated Adviser and Broker)

 

Aubrey Powell / Liz Yong

Corporate Finance

 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

 

Buchanan

 

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRPGUUWAUPMGQG
Date   Source Headline
9th Oct 20081:59 pmRNSMAJOR INTEREST IN SHARES
26th Sep 200811:10 amRNSCorporate Brokership
24th Sep 20087:00 amRNSBoard Appointment
19th Sep 20087:00 amRNSInterim Results
5th Sep 20087:00 amRNSNotice of Interim Results
7th May 20087:00 amRNSAGM Statement
9th Apr 20087:00 amRNSProject Update
3rd Apr 20087:00 amRNSAnnual Report and AGM Notice
31st Mar 20087:01 amRNSBoard Change
25th Mar 20087:01 amRNSAnnual Report and Accounts
13th Mar 20087:00 amRNSPreliminary Results
4th Mar 20087:01 amRNSNotification of Results
16th Jan 200812:31 pmRNSMajor Interest in Shares
10th Jan 20088:00 amRNSDirector's Share Transfer
3rd Jan 20088:00 amRNSDirector's Share Transfer
7th Dec 20077:00 amRNSLong Term Incentive Scheme
15th Nov 20077:01 amRNSIssue of Equity
24th Sep 20077:02 amRNSInterim Results
18th Sep 20077:00 amRNSNotice of Results
17th Sep 20079:08 amRNSMED2002 Licensing Deal
23rd Aug 20077:00 amRNSAppt of Pain Relief Adviser
14th Aug 20071:31 pmRNSHolding(s) in Company
9th Aug 20077:01 amRNSPositive Study Results
2nd Aug 20073:59 pmRNSHoldings in Company
27th Jul 20077:00 amRNSGrant Approval
19th Jul 20077:00 amRNSResult of AGM
20th Jun 20077:02 amRNSAnnual Report & Accounts
30th May 20077:02 amRNSFinal Results
25th May 200710:33 amRNSNotice of Preliminary Results
17th May 20077:01 amRNSHolding(s) in Company
14th May 20077:02 amRNSMED2002 Update
9th May 20077:02 amRNSCSD500 Patents granted
4th May 20077:01 amRNSConference Presentation
18th Apr 20077:01 amRNSDermaSys Agreement with GSK
22nd Mar 200711:02 amRNSHolding(s) in Company
20th Mar 20077:01 amRNSHolding(s) in Company
28th Feb 20077:01 amRNSLaunch of DermaSys Brand
31st Jan 20078:00 amRNSAdditional Listing
18th Jan 200712:52 pmRNSHolding(s) in Company
20th Dec 20067:01 amRNSTotal Voting Rights
16th Nov 20067:01 amRNSCSD500 Regulatory Update
12th Oct 20067:00 amRNSTechnical Seminar
21st Sep 20067:01 amRNSInterim Results
7th Sep 20067:00 amRNSNotice of Interim Results
6th Sep 20067:01 amRNSDCF100 Skin Study Results
17th Jul 20067:00 amRNSFLD500 Scale-up Trials
6th Jul 20067:01 amRNSNew Product Update
4th Jul 20062:44 pmRNSIssue of Equity
4th Jul 20062:39 pmRNSAgreement with GSK
27th Jun 20061:01 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.